FDA Clearance Tracker · K260935
Stelo Glucose Biosensor System
Last checked: Nov 20, 2026Latest source record: Jun 12, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Jun 12, 2026
Substantially Equivalent
Time to decision
84 days
Received Mar 20, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K260935
- Device name
- Stelo Glucose Biosensor System
- Applicant
- Dexcom, Inc.
- Applicant location
- San Diego, CA
- Received
- Mar 20, 2026
- Decided
- Jun 12, 2026
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device type
- Integrated Continuous Glucose Monitor For Non-Intensive Glucose Management, Over-The-Counter (SBH)
- Device class
- Class II
- Regulation
- 21 CFR 862.1355
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code SBH. The earliest in FDA's data is K233861, decided Jun 7, 2024.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K260935
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Dexcom, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K262472 · Decided Aug 11, 2026 · 25 days after receipt
Device type: Integrated Continuous Glucose Monitor For Non-Intensive Glucose Management, Over-The-Counter (SBH) · Laboratory Medicine & Pathology
- Dexcom G7 Continuous Glucose Monitoring System;Dexcom G7 15 Day Continuous Glucose Monitoring System510(k)
K261402 · Decided Jun 8, 2026 · 40 days after receipt
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ) · Laboratory Medicine & Pathology
K261359 · Decided May 21, 2026 · 27 days after receipt
Device type: Integrated Continuous Glucose Monitor For Non-Intensive Glucose Monitoring, Over-The-Counter (SAF) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.